Ikonisys Inc.

Two-year-old Ikonisys has developed a cell-based analysis system for detecting rare cells in blood. Its first application is detection of fetal cells in maternal blood, a longstanding ambition of many companies, none of which has succeeded to date. The test would detect the most common birth defects earlier in a pregnancy and more accurately than existing methods. Ikonisys also sees a big opportunity in cancer for early detection of disease and micrometastasis.

The idea for an automated image analyzer that could quickly scan samples came to Triantafyllos Tafas in the early 1980s as he stood in lakes studying microorganisms in drops of water. A hydrobiologist with a specialty in population dynamics and a PhD from the University of Athens in Greece, he was challenged by the inability of existing technologies to analyze large amounts of information, and foresaw the utility of computer-controlled imaging in biology.

At the same time, across the ocean, his friend Petros Tsipouras, MD, was working as a pediatric clinical geneticist at...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

Novartis Secures Approval For First Malaria Therapy for Babies

 
• By 

Coartem Baby to be rolled out in eight African countries in the autumn.

KalVista’s Delayed FDA Approval In HAE Comes Through

 
• By 

KalVista’s Ekterly obtains US approval as the first oral, on-demand therapy for hereditary angioedema. It will compete with established injectables.

Cogent Peaks With Bezaclastinib SUMMIT Results

 

The biotech announced positive topline results from the Phase II SUMMIT study in non-advanced systemic mastocytosis, with data for advanced SM and GIST expected later this year.

France’s AB Science Plots Pivotal Masitinib Trial In Prostate Cancer

 
• By 

Still holding out hope after multiple rejections for the tyrosine kinase inhibitor.

More from Business

Novartis Secures Approval For First Malaria Therapy for Babies

 
• By 

Coartem Baby to be rolled out in eight African countries in the autumn.

Finance Watch: A Mini-Surge In Follow-On Offerings Follows Positive Updates

 
• By 

Public Company Edition: A breakthrough designation, data and deals prompted big follow-on public offerings in late June and early July, including $402.5m for Cidara, $250.8m for Kymera and $230m for Dyne. Also, Revolution Medicines accessed up to $2bn from Royalty Pharma.

KalVista’s Delayed FDA Approval In HAE Comes Through

 
• By 

KalVista’s Ekterly obtains US approval as the first oral, on-demand therapy for hereditary angioedema. It will compete with established injectables.